1. Krogager ML et al.: Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. European Heart Journal 2017; 38: 104-112

2. Epstein M et al.: Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care 2015;21(Suppl):S212-20

3. Vukadinovic K et al.: True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: A meta-analysis. Am Heart J 2017;188:99-108

4. Weir MR et al.: Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors. N Engl J Med 2015; 372:211-221

5. Pitt B et al.: Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. European Heart J 2011;32: 820-828